Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

被引：37

作者：

Ozeki, Michio ^{[1
]}

Nozawa, Akifumi ^{[1
]}

Kanda, Kaori ^{[1
]}

Hori, Tomohiro ^{[1
]}

Nagano, Akihito ^{[2
]}

Shimada, Akira ^{[4
]}

Miyazaki, Tatsuhiko ^{[3
]}

Fukao, Toshiyuki ^{[1
]}

机构：

[1] Gifu Univ, Grad Sch Med, Dept Pediat, Yanagido 1-1, Gifu 5011194, Japan

[2] Gifu Univ, Grad Sch Med, Dept Orthoped Surg, Gifu, Japan

[3] Gifu Univ, Grad Sch Med, Dept Pathol, Gifu, Japan

[4] Okayama Univ, Dept Pediat, Grad Sch Med, Okayama, Japan

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2017年 / 39卷 / 06期

关键词：

soft tissue tumor; vascular tumor; mammalian target of rapamycin (mTOR) inhibitor; kaposiform hemangioendothelioma (KHE); phosphoinositide-3-kinase (PI3K); PLASMINOGEN-ACTIVATOR INHIBITOR-1; SARCOMA-LIKE HEMANGIOENDOTHELIOMA; KAPOSIFORM HEMANGIOENDOTHELIOMA; CANCER; SIROLIMUS; PAI-1;

D O I：

10.1097/MPH.0000000000000778

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.

引用

页码：E328 / E331

页数：4

共 50 条

[1] Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma
Gabor, Krisztina Mita
Sapi, Zoltan
Tiszlavicz, Lilla Gyorgyi
Fige, Anita
Bereczki, Csaba
Bartyik, Katalin
PEDIATRIC BLOOD & CANCER, 2018, 65 (02)
[2] Pseudomyogenic Hemangioendothelioma
Al-Qaderi, Ayah
Mansour, Ahmad T.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2019, 143 (06) : 763 - 767
[3] Pseudomyogenic Hemangioendothelioma
Ansai, Shin-ichi
Morimoto, Maya
Akaishi, Satoshi
JOURNAL OF NIPPON MEDICAL SCHOOL, 2019, 86 (02) : 126 - 130
[4] Pseudomyogenic Hemangioendothelioma
Horan, Nicholas A.
DiMaio, Dominick J.
CUTIS, 2017, 100 (06): : E13 - E16
[5] Pseudomyogenic Hemangioendothelioma
Zahn, A.
Guski, S.
Ruetten, A.
Ludwig-Peitsch, W.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 41 - 42
[6] Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma
Joseph, Jason
Wang, Wei-lien
Patnana, Madhavi
Ramesh, Naveen
Benjamin, Robert
Patel, Shreyaskumar
Ravi, Vinod
CLINICAL SARCOMA RESEARCH, 2015, 5
[7] Beyond the rare: a case of pseudomyogenic hemangioendothelioma treated sequentially with everolimus, denosumab, and pazopanib
Dias e Silva, Douglas
Gismondi, Camila Bobato Lara
Silva, Murilo Marques Almeida
Filipi, Renee Zon
Moura, Fernando
Jesus-Garcia, Reynaldo
Pestana, Roberto Carmagnani
EINSTEIN-SAO PAULO, 2024, 22
[8] Pseudomyogenic hemangioendothelioma in the spine
Klag, Elizabeth
Wakely, Paul E.
Scharschmidt, Thomas J.
CURRENT ORTHOPAEDIC PRACTICE, 2019, 30 (02): : 97 - 101
[9] Pazopanib as Treatment Option for Pseudomyogenic Hemangioendothelioma: A Case Report
Alhanash, Ali
Aseafan, Mohamed
Atallah, Jean
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
[10] Primary Pseudomyogenic Hemangioendothelioma of Bone
Inyang, Alero
Inwards, Carrie
Folpe, Andrew
Nielsen, G. Petur
Rosenberg, Andrew
LABORATORY INVESTIGATION, 2015, 95 : 19A - 19A

← 1 2 3 4 5 →